Mopetia (Paliperidone)

Paliperidone, the active ingredient in Mopetia, is a atypical antipsychotic presented as a unknown/intramuscular injection for intramuscular use. It treats schizophrenia and schizoaffective disorder in adults.\n\nGNH India supplies Mopetia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic indicated for disorders within the schizophrenia spectrum.\n\nSchizophrenia: reduces psychotic symptoms and helps maintain long‑term stability.\nSchizoaffective disorder: controls both mood and psychotic features.\nMaintenance treatment of schizophrenia: provides ongoing relapse prevention after acute control.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Injection site pain or erythema\n- Akathisia or restlessness\n- Weight gain\n- Somnolence or fatigue\n- Dizziness\n- Elevated prolactin levels\n\nSerious or Rare Side Effects:\n- Neuroleptic malignant syndrome\n- Tardive dyskinesia\n- Severe hypotension or cardiac arrhythmias\n- Agranulocytosis or severe neutropenia

When prescribing Paliperidone, clinicians should consider several safety measures.\n\nPregnancy: evaluate risk‑benefit ratio; limited data available.\nBreastfeeding: assess potential infant exposure; caution advised.\nCardiovascular: monitor ECG for QT prolongation and blood pressure changes.\nMetabolic: regularly check weight, glucose, and lipid profiles.\nElderly: use with caution due to increased fall and sedation risk.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase plasma levels.\n- QT‑prolonging agents (e.g., quinidine, haloperidol) can heighten cardiac risk.\n- CNS depressants (e.g., benzodiazepines) may enhance sedation.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce efficacy.\n- Antihypertensive drugs may have additive blood‑pressure effects.\n- Anticholinergic medications can worsen cognitive side effects.